IFP Advisors
GLUE icon

IFP Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

IFP Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.5K Sell
1,132
-46
-4% -$788 ﹤0.01% 3195
2026
Q2 		$28.5K Sell
1,178
-17
-1% -$321 ﹤0.01% 2747
2026
Q1 		$19.7K Sell
1,195
-23
-2% -$440 ﹤0.01% 2785
2025
Q4 		$19.1K Buy
1,218
+66
+6% +$889 ﹤0.01% 2747
2025
Q3 		$8.54K Sell
1,152
-30
-3% -$159 ﹤0.01% 2987
2025
Q2 		$5.33K Buy
+1,182
New +$5.27K ﹤0.01% 3335
2025
Q1 		– Hold
0
– – – 4123
2024
Q4 		– Hold
0
– – – 4306

Other funds holding GLUE

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

IFP Advisors's GLUE Position: Q3 2026 in Review

IFP Advisors reduced its Monte Rosa Therapeutics (GLUE) stake by 3.9% in Q3 2026, selling an estimated $788 and leaving 1,132 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

IFP Advisors first reported a position in GLUE in Q2 2025 and has held it in 6 quarters since. The position peaked at $28.5K in Q2 2026. 91 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • IFP Advisors held 1,132 shares of Monte Rosa Therapeutics worth $13.5K as of Q3 2026.
  • IFP Advisors sold 46 Monte Rosa Therapeutics shares in Q3 2026, an estimated $788.
  • Monte Rosa Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3195 holding.
  • IFP Advisors first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • IFP Advisors's Monte Rosa Therapeutics position peaked at $28.5K in Q2 2026.
  • 91 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.